In a recent study posted to the medRxiv* preprint server, researchers assessed the efficacy of a third dose of coronavirus disease 2019 (COVID-19) vaccine in anti-CD20 antibody-treated individuals.

Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...

Anti-CD20 monoclonal antibodies are a class of therapeutic antibodies that target a specific protein called CD20 found on the surface of B cells, a type of white blood cell. These antibodies are ...

As East Asia prepares to shut down for the Lunar New Year holiday and looks towards the Year of the Snake, it’s time to look back at bitcoin BTC $67,935.47 and the CoinDesk 20 (CD20)’s performance ...

Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have been ...

Studies have shown that age and male sex are the key drivers for severe COVID-19, apart from other factors such as preexisting autoimmune conditions and malignancy. Scientists across the globe agree ...

Antibodies directed against the protein CD20, which is expressed by immune cells known as B cells, are used to treat B cell non-Hodgkin lymphoma and rheumatoid arthritis. Despite this, the function of ...

The results of Phase III trials of the CD20-targeted human monoclonal antibody (mAb) ofatumumab in rheumatoid arthritis and non-Hodgkin's lymphoma (NHL) dampen hopes on the potential of the drug to ...

Seventeen patients with R/R MCL received a single dose of LV20.19 CAR T cells at 2.5 × 10 6 cells/kg (phase I = three patients; phase II = 14 patients). The best overall response rate (ORR) was 100% ...

For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-treated and untreated, according to a ...

MRD-guided retreatment with anti-CD20 antibodies may improve survival outcomes in high-risk, relapsed CLL patients by initiating therapy before clinical relapse. The study showed MRD-triggered ...